- Trials with a EudraCT protocol (121)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
121 result(s) found for: Legal psychology.
Displaying page 1 of 7.
EudraCT Number: 2021-002011-61 | Sponsor Protocol Number: 77267 | Start Date*: 2021-08-13 |
Sponsor Name:Academisch ziekenhuis Maastricht | ||
Full Title: The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome | ||
Medical condition: 22q11.2 deletion syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003660-11 | Sponsor Protocol Number: 74817 | Start Date*: Information not available in EudraCT |
Sponsor Name:Accare | ||
Full Title: Do effects of methylphenidate decline after long-term use? A double-blind, placebo-controlled cross-over study of effects of methylphenidate on cognitive functioning and real world behavior in trea... | ||
Medical condition: Attention Deficit Hyperactivity Disorder (ADHD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023208-29 | Sponsor Protocol Number: OXT-003 | Start Date*: 2011-08-02 |
Sponsor Name:Rheinische Friedrich-Wilhelms-University of Bonn | ||
Full Title: Effects of Oxytocin on opioide withdrawal symptoms | ||
Medical condition: Individuals with opioid dependence who are voluntary inpatients from detoxification unit are investigated. The opioid withdrawal symptome are observed. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003588-85 | Sponsor Protocol Number: PSYCHIC | Start Date*: 2022-01-11 |
Sponsor Name:UCLouvain | ||
Full Title: Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders- How to conciliate plasma concentrations, clinical response and genetic factors ? | ||
Medical condition: Schizophrenia, schizoaffective disorders, psychosis not otherwise specified, and dellusional disorders | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003733-15 | Sponsor Protocol Number: B-003 | Start Date*: 2013-11-13 |
Sponsor Name:VU University medical center | ||
Full Title: The Dutch CSF and PET Biomarker Concordance of Alzheimer’s Disease pathology study | ||
Medical condition: Patients visiting the VUmc Alzheimer Center with objective cognitive complaints or diagnosed with Alzheimer's Disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003385-24 | Sponsor Protocol Number: 2815 | Start Date*: 2016-09-28 |
Sponsor Name:GGZ inGeest, parner VUmc | ||
Full Title: The Recall-study: Rivastigmine for ECT-induced Cognitive Adverse effects in Late Life Depression: a multicenter, randomized, double-blind, placebo-controlled, crossover trial | ||
Medical condition: Interictal delirium during electric convulsive therapy- course | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003718-10 | Sponsor Protocol Number: 2014RISP-ID01 | Start Date*: 2015-09-15 |
Sponsor Name:UMCG | ||
Full Title: A placebo-controlled discontinuation trial of off-label used risperidone in people with intellectual disability | ||
Medical condition: no specific condition, we will investigate people with intellectual disability who have been using risperidone on an off-label basis for at least one year. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005078-25 | Sponsor Protocol Number: CHUBX2019/59 | Start Date*: 2023-01-25 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Phase III randomized, multicenter open label study to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity. | ||
Medical condition: Mental and behavioral disorders (F00-F99) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022686-10 | Sponsor Protocol Number: 578001.01.012 | Start Date*: 2011-06-08 |
Sponsor Name:Dr. W. Schwabe GmbH & Co. KG | ||
Full Title: Multi-centre, open-label clinical trial to evaluate the efficacy and safety of Rhodiola rosea extract WS® 1375 in Subjects with Burnout Symptoms | ||
Medical condition: Burnout symptoms like exhaustion, fatigue, mild anxiety, mood disturbances | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004958-34 | Sponsor Protocol Number: UNOLE0457 | Start Date*: 2015-01-30 |
Sponsor Name:University of Leicester | ||
Full Title: Midazolam Measurement and Modelling using Matrix Samplers | ||
Medical condition: Not applicable | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000118-31 | Sponsor Protocol Number: CCTU0145 | Start Date*: 2017-01-16 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | ||
Full Title: A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2) | ||
Medical condition: Antibody associated Psychosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000989-38 | Sponsor Protocol Number: WP40877 | Start Date*: 2019-11-04 | ||||||||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE Ib, MULTICENTER, OPEN-LABEL, 6-WEEK STUDY WITH A 48 WEEK EXTENSION TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF BALOVAPTAN IN CHILDREN AGES 2-4 YEARS WITH AUTISM SPECTRU... | ||||||||||||||||||
Medical condition: Autism spectrum disorder (ASD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002713-35 | Sponsor Protocol Number: AXCT01-01-03-2013 | Start Date*: 2014-07-29 | |||||||||||
Sponsor Name:MediPsych SA | |||||||||||||
Full Title: Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001567-37 | Sponsor Protocol Number: KUKIDEX-2 | Start Date*: 2016-11-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Efficacy of single dose intranasal dexmedetomidine for conscious sedation in dental practice in dentophobic uncooperative patients with intellectual disability. | ||
Medical condition: dentophobia intellectual disability | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024202-34 | Sponsor Protocol Number: 24122010 | Start Date*: 2014-04-24 | |||||||||||
Sponsor Name:UNIVERSITÄTSMEDIZIN GÖTTINGEN, GEORG-AUGUST-UNIVERSITÄT,Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie | |||||||||||||
Full Title: Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder | |||||||||||||
Medical condition: high-functioning autismus spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F84.1) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004049-19 | Sponsor Protocol Number: NL77938.018.23 | Start Date*: 2023-10-13 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Sodium oxybate as a potential new treatment for catatonia in patients with depression, bipolar disorder or a psychotic disorder, a randomized controlled trial. The Laborit study. | ||
Medical condition: Catatonia in patients with depression, bipolar disorder or a psychotic disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004088-26 | Sponsor Protocol Number: A1281201 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: 26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC) | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004973-42 | Sponsor Protocol Number: 1289.32 | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter... | |||||||||||||
Medical condition: attenuated psychosis syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001056-17 | Sponsor Protocol Number: 3606 | Start Date*: 2020-08-14 | ||||||||||||||||
Sponsor Name:Kings's College London [...] | ||||||||||||||||||
Full Title: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia. | ||||||||||||||||||
Medical condition: Clinically significant agitation in Alzheimer's Diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001599-46 | Sponsor Protocol Number: F1J-MC-HMGI | Start Date*: 2017-05-09 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder | ||
Medical condition: Generalized Anxiety Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
